GLP1受体激素改变前列腺癌的生长和治疗反应
Soumen Bera1,2, Lisa C Gutgesell3, Brynne Darden4
1Department of Pathology, The University of Illinois Chicago, Chicago, Illinois, USA.
类似葡萄糖类-1受体 (GLP1R) 激动剂,如塞马格卢提德,通过抑制细胞生长和信号通路,在治疗晚期前列腺癌方面表现有前途. 这些发现表明GLP1R激动因子是前列腺癌的潜在治疗策略.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 葡萄糖类-1受体 (GLP1R) 激动剂广泛用于2型糖尿病和肥胖症.
- 在晚期前列腺癌中表达GLP1R,这表明GLP1R在癌症信号传递中发挥了直接作用.
- 代谢障碍在前列腺癌患者中很常见,因此需要了解塞马格卢的作用.
研究的目的:
- 调查GLP1R对前列腺癌细胞的影响.
- 在前列腺癌模型中确定单独或与恩扎卢胺一起的塞马格卢胺的治疗潜力.
- 探索GLP1R表达与前列腺癌特征之间的关联,包括神经内分泌分化和信号通路.
主要方法:
- 在实验室研究中,使用用semaglutide治疗的前列腺癌模型.
- 评估细胞增殖,糖解功能和信号通路 (cAMP水平,氨酶活性).
- 在跨差异化模型中分析GLP1R和雄激素受体 (AR) 表达.
- 对公开可用的患者RNA测序数据的生物信息分析 (n=664).
主要成果:
- 塞马格卢提德降低了前列腺癌细胞的增殖,糖解质功能和氨酶信号传递.
- GLP1R激动性降低了cAMP水平,与抑制GPCR信号传递相一致.
- 塞马格卢胺降低了单独或与恩扎胺结合的细胞增殖.
- GLP1R表达与AR负相关,与神经内分泌前列腺癌 (NEPC) 标志物正相关.
- 晚期前列腺癌中GLP1R表达较高与负的Notch信号相关.
结论:
- 通过semaglutide,GLP1R激动性抑制了前列腺癌细胞的瘤信号传递和生长.
- 塞马格卢提德显示出作为晚期前列腺癌的独立或辅助疗法的潜力.
- GLP1R信号传递可能在过渡到神经内分泌前列腺癌中发挥作用.
- 准GLP1R是一种有前途的前列腺癌治疗策略.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GPCRs Regulate Adenylyl Cylase Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Mitogens and the Cell Cycle
GPCR Desensitization
